- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 5 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 124
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
- Interventions
- OPT-302, Lucentis™
- Drug
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- avacincaptad pegol, Sham
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more
- Conditions
- Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
- Interventions
- Prescreening Assessments
- Diagnostic Test
- Lead sponsor
- Ascidian Therapeutics, Inc
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 8
- States / cities
- San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 5 more
- Conditions
- Stargardt Disease
- Interventions
- AAVB-039
- Biological
- Lead sponsor
- AAVantgarde Bio Srl
- Industry
- Eligibility
- 8 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
- Interventions
- Retinal imaging
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
- Interventions
- ACDN-01
- Drug
- Lead sponsor
- Ascidian Therapeutics, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 10
- States / cities
- San Francisco, California • Gainesville, Florida • Miami, Florida + 7 more
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
- Interventions
- ALK-001
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Interventions
- No Intervention
- Other
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Palo Alto, California • Sacramento, California + 12 more
- Conditions
- STGD1, Stargardt Disease 1
- Interventions
- Tinlarebant, Placebo
- Drug
- Lead sponsor
- Belite Bio, Inc
- Industry
- Eligibility
- 12 Years to 20 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more
- Conditions
- Macular Degeneration
- Interventions
- intravitreal injection Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Stargardt Disease
- Interventions
- RTx-021
- Genetic
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Bakersfield, California • Pittsburgh, Pennsylvania • Bellaire, Texas
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
- Interventions
- ALK-001, Placebo
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more
- Conditions
- Stargardt Disease, Macular Atrophy
- Interventions
- Emixustat
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
- Interventions
- Anterior Chamber (AC) Tap
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- La Jolla, California • Redlands, California • Santa Maria, California + 44 more
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- GT005
- Genetic
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
- Conditions
- Macular Dystrophy, Corneal
- Interventions
- 4-Methylpyrazole, saline
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
- Interventions
- brolucuzumab 6 mg IVT
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Abilene, Texas
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Interventions
- SB-007
- Genetic
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more